Toll Like Receptor 3 - Pipeline Review, H2 2020
Toll Like Receptor 3 - Pipeline Review, H2 2020
SUMMARY
According to the recently published report 'Toll Like Receptor 3 - Pipeline Review, H2 2020'; Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response.
The report 'Toll Like Receptor 3 - Pipeline Review, H2 2020' outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Immunology, Central Nervous System and Respiratory which include indications Melanoma, Bladder Cancer, Breast Cancer, Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Ovarian Cancer, Peritoneal Cancer, Renal Cell Carcinoma, Severe Acute Respiratory Syndrome (SARS), Triple-Negative Breast Cancer (TNBC), Acute Inflammation, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Cytomegalovirus (HHV-5) Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Fallopian Tube Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Herpes Labialis (Oral Herpes), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Influenza A Virus, H5N1 Subtype Infections, Influenza A Virus, H7N9 Subtype Infections, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Neuroendocrine Tumors, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Solid Tumor, Ulcerative Colitis, Unspecified Influenza Virus Infections, West Nile Virus Infections and Zika Virus Infections
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Toll Like Receptor 3 - Pipeline Review, H2 2020'; Toll Like Receptor 3 (CD283 or TLR3) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 3 (CD283 or TLR3) - Toll-like receptor 3 (TLR3) is a protein encoded by the TLR3 gene. It control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR3 is a nucleotide-sensing TLR which is activated by double-stranded RNA, a sign of viral infection. It acts via the adapter TRIF/TICAM1, leading to NF-kappa-B activation, IRF3 nuclear translocation, cytokine secretion and the inflammatory response.
The report 'Toll Like Receptor 3 - Pipeline Review, H2 2020' outlays comprehensive information on the Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Immunology, Central Nervous System and Respiratory which include indications Melanoma, Bladder Cancer, Breast Cancer, Coronavirus Disease 2019 (COVID-19), Epithelial Ovarian Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Ovarian Cancer, Peritoneal Cancer, Renal Cell Carcinoma, Severe Acute Respiratory Syndrome (SARS), Triple-Negative Breast Cancer (TNBC), Acute Inflammation, Chronic Fatigue Syndrome (Myalgic Encephalomyelitis), Chronic Inflammation, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Cytomegalovirus (HHV-5) Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Fallopian Tube Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hepatitis B, Herpes Labialis (Oral Herpes), Inflammation, Influenza A Virus, H3N2 Subtype Infections, Influenza A Virus, H5N1 Subtype Infections, Influenza A Virus, H7N9 Subtype Infections, Malignant Pleural Mesothelioma, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Neuroendocrine Tumors, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Small Cell Lung Cancer, Pancreatic Cancer, Pandemic Influenza, Prostate Cancer, Pulmonary Inflammation, Rhinovirus Infections, Sarcomas, Solid Tumor, Ulcerative Colitis, Unspecified Influenza Virus Infections, West Nile Virus Infections and Zika Virus Infections
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 3 (CD283 or TLR3)
- The report reviews Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 3 (CD283 or TLR3) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 3 (CD283 or TLR3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 3 (CD283 or TLR3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
13therapeutics Inc
AIM ImmunoTech Inc
Glysantis Inc
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Toll Like Receptor 3 (CD283 or TLR3) - Overview
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 3 (CD283 or TLR3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 3 (CD283 or TLR3) - Companies Involved in Therapeutics Development
13therapeutics Inc
AIM ImmunoTech Inc
Glysantis Inc
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd
Toll Like Receptor 3 (CD283 or TLR3) - Drug Profiles
Antibody to Antagonize TLR3 for Acute and Chronic Inflammatory Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 3 (CD283 or TLR3) - Dormant Products
Toll Like Receptor 3 (CD283 or TLR3) - Discontinued Products
Toll Like Receptor 3 (CD283 or TLR3) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by 13therapeutics Inc, H2 2020
Pipeline by AIM ImmunoTech Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by 13therapeutics Inc, H2 2020
Pipeline by AIM ImmunoTech Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Dormant Products, H2 2020 (Contd..2), H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
13therapeutics Inc
AIM ImmunoTech Inc
Glysantis Inc
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
13therapeutics Inc
AIM ImmunoTech Inc
Glysantis Inc
Highlight Therapeutics SL
Oncovir Inc
PrEP Biopharm Ltd
Provention Bio Inc
Tollys SAS
Yisheng Biopharma Co Ltd
